A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson's Disease-Reference-Cited by-同舟云学术

A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson's Disease

Published:2022-07-28 Issue:9 Volume:11 Page:1068-1077
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Stocchi Fabrizio¹,Peckham Elizabeth L.²,De Pandis Maria Francesca³,Sciarappa Ken⁴,Kleiman Robert⁵,Agbo Felix⁶,Olanow C. Warren⁷⁸,Blum David⁴,Navia Bradford⁴

Affiliation:

1. University San Raffaele and Institute for Research and Medical Care, IRCCS San Raffaele Pisana Rome Italy

2. Central Texas Neurology Consultants Round Rock Texas USA

3. San Raffaele Cassino Tosinvest Sanità Cassino Italy

4. Sunovion Pharmaceuticals Inc. Marlborough Massachusetts USA

5. eResearch Technology Inc. Philadelphia Pennsylvania USA

6. Sunovion Pharmaceuticals Inc. Teaneck New Jersey USA

7. Mount Sinai School of Medicine New York New York USA

8. Clintrex Sarasota Florida USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1147

Reference30 articles.

1. Diagnosis and Treatment of Parkinson Disease

2. Prevalence of Parkinson’s disease across North America

3. Levodopa: A new look at an old friend

4. The scientific and clinical basis for the treatment of Parkinson disease (2009)

5. The spectrum of “off” in Parkinson's disease: What have we learned over 40 years?

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sublingual apomorphine in the treatment of Parkinson’s disease;Journal of Neural Transmission;2024-05-14

2. Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients;Clinical and Translational Science;2024-05

3. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson’s disease complicated by OFF episodes: a phase 3, open-label study;Journal of Neurology;2024-03-28